MX2022012310A - Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. - Google Patents

Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.

Info

Publication number
MX2022012310A
MX2022012310A MX2022012310A MX2022012310A MX2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A
Authority
MX
Mexico
Prior art keywords
methods
multiple sclerosis
bruton
inhibitor
tyrosine kinase
Prior art date
Application number
MX2022012310A
Other languages
English (en)
Spanish (es)
Inventor
Hideki Garren
Edmond Huatung Teng
Aurelien Viaccoz
BUEDINGEN Hans- Christian VON
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2022012310A publication Critical patent/MX2022012310A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2022012310A 2020-04-03 2021-04-01 Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. MX2022012310A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063005095P 2020-04-03 2020-04-03
US202063051767P 2020-07-14 2020-07-14
PCT/US2021/025301 WO2021202825A1 (en) 2020-04-03 2021-04-01 Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
MX2022012310A true MX2022012310A (es) 2022-10-27

Family

ID=75625678

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012310A MX2022012310A (es) 2020-04-03 2021-04-01 Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.

Country Status (13)

Country Link
US (1) US12605376B2 (https=)
EP (1) EP4125906A1 (https=)
JP (1) JP2023520469A (https=)
KR (1) KR20220163986A (https=)
CN (1) CN115916205A (https=)
AU (1) AU2021249129A1 (https=)
BR (1) BR112022019846A2 (https=)
CA (1) CA3177390A1 (https=)
CL (1) CL2022002699A1 (https=)
IL (1) IL296990A (https=)
MX (1) MX2022012310A (https=)
TW (1) TWI907406B (https=)
WO (1) WO2021202825A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010513A (es) * 2020-02-28 2022-09-21 Genentech Inc Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.
KR102933902B1 (ko) 2021-05-14 2026-03-05 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 공결정질 형태
CN114028393B (zh) * 2021-11-07 2023-07-18 天津医科大学 阿帕替尼在制备治疗多发性硬化症药物的用途
WO2024238524A1 (en) * 2023-05-16 2024-11-21 Genentech, Inc. Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
SG11201700849XA (en) 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
EP4049660B1 (en) 2016-02-29 2025-02-19 F. Hoffmann-La Roche AG Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
CN107043366B (zh) 2017-04-25 2020-05-26 中国药科大学 4-氨基嘧啶类化合物、其制备方法及医药用途
MX393601B (es) 2017-05-18 2025-03-21 Jiangsu Hengrui Medicine Co Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
WO2019208805A1 (ja) * 2018-04-27 2019-10-31 小野薬品工業株式会社 Btk阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および/または治療剤
CN112512527A (zh) * 2018-09-12 2021-03-16 杭州索元生物医药股份有限公司 恩扎妥林和btk抑制剂的组合及其用途
CN113423401A (zh) 2019-01-22 2021-09-21 豪夫迈·罗氏有限公司 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法
MX2022010513A (es) 2020-02-28 2022-09-21 Genentech Inc Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.

Also Published As

Publication number Publication date
US12605376B2 (en) 2026-04-21
KR20220163986A (ko) 2022-12-12
BR112022019846A2 (pt) 2022-11-22
CA3177390A1 (en) 2021-10-07
WO2021202825A1 (en) 2021-10-07
CN115916205A (zh) 2023-04-04
US20230149395A1 (en) 2023-05-18
TWI907406B (zh) 2025-12-11
IL296990A (en) 2022-12-01
EP4125906A1 (en) 2023-02-08
TW202203925A (zh) 2022-02-01
CL2022002699A1 (es) 2023-03-31
JP2023520469A (ja) 2023-05-17
AU2021249129A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
MX2022012310A (es) Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.
MX2022013647A (es) Imidazopiridazinas como moduladores de il-17.
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
PH12019502334A1 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
EP1933833B8 (en) Therapy for the treatment of overactive bladder
MX2024013020A (es) Compuestos de heteroarilo para el tratamiento del dolor
CR20240514A (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2024014626A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton
EP4520398A3 (en) Treatment of prostate cancer
FI3972603T3 (fi) Menetelmiä sjögrenin oireyhtymän hoitamiseksi käyttäen brutonin tyrosiinikinaasin estäjää
ZA202000028B (en) Use of vibegron to treat overactive bladder
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
AU2021322255A8 (en) Use of dexpramipexole for the treatment of moderate to severe asthma
MX2025008009A (es) Moduladores de la proteolisis de bcl6 y metodos de uso asociados
MX2022010513A (es) Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
WO2021239928A3 (en) Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
PH12021551975A1 (en) Use of vibegron to treat overactive bladder
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
MX2025000582A (es) Inhibidores de tirosina cinasa 2 y usos de estos
ZA202407245B (en) Novel use of pitolisant for treating severe fatigue
MX2022007304A (es) Uso de lemborexant para tratamiento del insomnio.